Andy Futreal, Ph.D.
The age of precision medicine is upon us. Though we have witnessed practice-changing examples of how genomic information can be translated into more effective therapies for people with cancer, there is still a great deal to learn.
The Genomic Medicine department aims to advance cancer care via an integrated approach across the MD Anderson community and ultimately around the globe. The diverse faculty and staff within the department consist of primary faculty in genomic medicine, adjunct faculty with dual appointment in other departments, and numerous outstanding individuals (faculty and staff) dedicated to advancing cancer care through technology and innovation.
Our multifaceted program has several components:
- Discovery efforts to characterize somatic epi/genomic alterations and germline variations in multiple cancer types (through the Cancer Genomics Laboratory and other independent laboratories within Genomic Medicine), and efforts to understand the complex interplay between cancer genomics and anti-tumor immune responses
- Functional characterization and mechanistic studies to identify those differences that are most likely to be relevant to disease, with the identification and validation of therapeutic targets and biomarkers utilizing diverse model systems (in collaboration with the Institute for Applied Cancer Science - IACS, the Center for Co-Clinical Trials - CCCT, and the Oncology Research for Biologics and Immunotherapy Translation – ORBIT)
- Translational efforts with clinical samples and associated clinical and research data in collaboration with MD Anderson clinicians and investigators within and outside of the Moon Shot Program™ and APOLLO (Adaptive Patient-Oriented Longitudinal Learning and Optimization) and Big Data platforms.
Congratulations to our Chair, Andy Futreal, PhD, for being awarded the 2018 Emil Frei, III Award for Excellence in Translational Research at Cancer Medicine’s 13th Annual Faculty Recognition & Awards Program on December 7, 2018.
Related Programs & Labs